Atorvastatin vs Rosuvastatin

Both atorvastatin and rosuvastatin are classified as high-intensity statins at their upper doses, but rosuvastatin is more potent on a milligram-per-milligram basis. The STELLAR trial ^[1] (2003) directly compared these statins across dose ranges and found that rosuvastatin achieved greater LDL reductions at comparable doses: rosuvastatin 10 mg ^[1][4] reduced LDL by approximately 46%, while atorvastatin 10 mg reduced LDL by approximately 37%.

At maximum doses, rosuvastatin 40 mg can reduce LDL by up to 55-63%, while atorvastatin 80 mg reduces LDL by approximately 50-60%. For patients who need aggressive LDL lowering, rosuvastatin may achieve target levels at lower doses.

Rosuvastatin also raises HDL cholesterol ("good" cholesterol) more effectively than atorvastatin. In the STELLAR trial ^[1], rosuvastatin increased HDL by 8-14% across doses, compared to 2-8% for atorvastatin. Both medications reduce triglycerides, with atorvastatin showing slightly greater triglyceride reduction at higher doses.

The JUPITER trial ^[2] (2008) demonstrated that rosuvastatin 20 mg significantly reduced cardiovascular events by 44% in apparently healthy individuals with elevated high-sensitivity C-reactive protein (hsCRP). The landmark trials for atorvastatin include ASCOT-LLA and TNT, which established its role in primary and secondary prevention.

Both statins have extensive evidence supporting cardiovascular event reduction. No head-to-head outcomes trial has demonstrated superiority of one over the other for preventing heart attacks or strokes.

Both statins share common side effects typical of the class. Muscle-related complaints are the most frequently cited reason for statin discontinuation, affecting an estimated 5-10% of patients in clinical practice (though placebo-controlled trials show lower rates).

Myalgia (muscle pain without CK elevation) occurs in 5-10% of patients with both drugs. True myopathy (muscle pain with elevated CK) is rare, affecting less than 0.1% of patients. Rhabdomyolysis is extremely rare with both medications.

Atorvastatin is metabolized primarily by the CYP3A4 enzyme, which means it has more potential drug interactions with medications that inhibit this pathway (such as certain antibiotics, antifungals, and calcium channel blockers). Rosuvastatin has minimal CYP metabolism, reducing the risk of drug-drug interactions.

Both statins can cause modest elevations in liver enzymes (transaminases) and blood glucose levels. The diabetes risk is a class effect, with slightly higher risk associated with high-intensity therapy. A 2010 meta-analysis in The Lancet suggested that statin-associated diabetes risk is small and outweighed by cardiovascular benefits.

GI side effects (nausea, diarrhea, constipation) occur in approximately 5-10% of patients with either drug. Headache and dizziness are occasionally reported.

Both Lipitor and Crestor are available as affordable generics. Generic atorvastatin ^[3] typically costs $4-$10 per month and is one of the most commonly dispensed medications in the country. Generic rosuvastatin ^[4] costs approximately $8-$20 per month — slightly more but still very affordable.

Brand-name versions are rarely dispensed, as patent exclusivity for both drugs expired years ago. Both generics are routinely covered by all insurance plans and appear on $4 generic lists ^[3] at major pharmacy chains. Cost is rarely a significant factor in the choice between these two medications.

For patients without insurance, generic pricing through discount pharmacy programs like GoodRx, RxSaver, or Costco pharmacy makes either medication accessible for under $15 per month.

Both Lipitor and Crestor are taken orally once daily ^[3][4]. Atorvastatin can be taken at any time of day with or without food, offering maximum flexibility. Rosuvastatin can also be taken at any time, with or without food.

Neither medication requires routine blood monitoring beyond periodic lipid panels (typically every 3-12 months) to assess treatment effectiveness. Liver function tests are no longer required by current guidelines for routine monitoring, though they may be checked at baseline.

Dose adjustments are straightforward for both: providers typically start at a moderate dose and titrate based on LDL response. Both medications are available in a range of tablet strengths.

For most patients, the choice between Lipitor and Crestor comes down to clinical nuances rather than dramatic differences. Crestor (rosuvastatin) may be preferred when maximum LDL reduction is needed, as it achieves greater reductions at equivalent doses. It may also be preferred in patients taking multiple medications due to its lower potential for drug interactions.

Lipitor (atorvastatin) may be preferred when cost is the primary consideration, as generic atorvastatin is typically the least expensive option. It also has the longest track record and most extensive clinical trial database of any statin.

Patients with kidney impairment should use rosuvastatin cautiously, as it is partly renally cleared. Atorvastatin may be preferred in this population. Asian patients may metabolize rosuvastatin differently and often require lower starting doses (5 mg) per FDA labeling.

If you experience muscle symptoms on one statin, switching to the other is a reasonable strategy. Response to statins varies individually, and many patients who cannot tolerate one statin can tolerate another. Always work with your healthcare provider to optimize your cholesterol management.